It has been shown that ER+/HER2- (Luminal A) tumors express AR (by IHC) more frequently than other IHC-surrogate subtypes and, in this BC subset, AR was considered an independent biomarker of positive outcome [3,24,25]. This evidence concerns the gene ESR1 and breast cancer.